1. Home
  2. MIN vs TENX Comparison

MIN vs TENX Comparison

Compare MIN & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MFS Intermediate Income Trust

MIN

MFS Intermediate Income Trust

N/A

Current Price

$2.45

Market Cap

278.8M

Sector

Finance

ML Signal

N/A

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

N/A

Current Price

$10.45

Market Cap

317.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MIN
TENX
Founded
1988
1967
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
278.8M
317.8M
IPO Year
N/A
2001

Fundamental Metrics

Financial Performance
Metric
MIN
TENX
Price
$2.45
$10.45
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$29.67
AVG Volume (30 Days)
148.2K
596.0K
Earning Date
01-01-0001
05-15-2026
Dividend Yield
7.31%
N/A
EPS Growth
N/A
N/A
EPS
0.08
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$30.63
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.41
$5.34
52 Week High
$2.72
$18.38

Technical Indicators

Market Signals
Indicator
MIN
TENX
Relative Strength Index (RSI) 48.64 33.52
Support Level $2.41 $6.40
Resistance Level $2.52 $14.15
Average True Range (ATR) 0.02 0.64
MACD 0.00 -0.07
Stochastic Oscillator 42.86 8.40

Price Performance

Historical Comparison
MIN
TENX

About MIN MFS Intermediate Income Trust

MFS Intermediate Income Trust is a diversified closed-end management investment company. The fund's investment objective is to seek high current income but may also consider capital appreciation. It invests the assets in debt instruments. Its portfolio of investments comprises different sector investments such as the automotive, chemicals, energy, food and beverages, insurance, and other sectors.

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

Share on Social Networks: